168 related articles for article (PubMed ID: 15225612)
1. Novel human CYP2A6 alleles confound gene deletion analysis.
Nakajima M; Yoshida R; Fukami T; McLeod HL; Yokoi T
FEBS Lett; 2004 Jul; 569(1-3):75-81. PubMed ID: 15225612
[TBL] [Abstract][Full Text] [Related]
2. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
3. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
4. CYP2A6 polymorphism reveals differences in Japan and the existence of a specific variant in Ovambo and Turk populations.
Takeshita H; Hieda Y; Fujihara J; Xue Y; Nakagami N; Takayama K; Imamura S; Kataoka K
Hum Biol; 2006 Apr; 78(2):235-42. PubMed ID: 17036930
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Paschke T; Riefler M; Schuler-Metz A; Wolz L; Scherer G; McBride CM; Bepler G
Toxicology; 2001 Nov; 168(3):259-68. PubMed ID: 11684323
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese.
Ariyoshi N; Sekine H; Saito K; Kamataki T
Pharmacogenetics; 2002 Aug; 12(6):501-4. PubMed ID: 12172220
[TBL] [Abstract][Full Text] [Related]
7. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
8. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
[TBL] [Abstract][Full Text] [Related]
9. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T
Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.
Oscarson M; McLellan RA; Asp V; Ledesma M; Bernal Ruiz ML; Sinues B; Rautio A; Ingelman-Sundberg M
Hum Mutat; 2002 Oct; 20(4):275-83. PubMed ID: 12325023
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
Oscarson M; McLellan RA; Gullstén H; Agúndez JA; Benítez J; Rautio A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Oct; 460(2):321-7. PubMed ID: 10544257
[TBL] [Abstract][Full Text] [Related]
12. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP.
Kitagawa K; Kunugita N; Katoh T; Yang M; Kawamoto T
Biochem Biophys Res Commun; 1999 Aug; 262(1):146-51. PubMed ID: 10448083
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.
Gyamfi MA; Fujieda M; Kiyotani K; Yamazaki H; Kamataki T
Eur J Clin Pharmacol; 2005 Feb; 60(12):855-7. PubMed ID: 15660270
[TBL] [Abstract][Full Text] [Related]
14. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
15. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.
Oscarson M; McLellan RA; Gullstén H; Yue QY; Lang MA; Bernal ML; Sinues B; Hirvonen A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Apr; 448(1):105-10. PubMed ID: 10217419
[TBL] [Abstract][Full Text] [Related]
16. CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro.
Rossini A; Lima SS; Rapozo DC; Faria M; Albano RM; Pinto LF
Braz J Med Biol Res; 2006 Feb; 39(2):195-201. PubMed ID: 16470306
[TBL] [Abstract][Full Text] [Related]
17. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
Yamanaka H; Nakajima M; Nishimura K; Yoshida R; Fukami T; Katoh M; Yokoi T
Eur J Pharm Sci; 2004 Aug; 22(5):419-25. PubMed ID: 15265511
[TBL] [Abstract][Full Text] [Related]
18. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).
Nunoya K; Yokoi T; Kimura K; Inoue K; Kodama T; Funayama M; Nagashima K; Funae Y; Green C; Kinoshita M; Kamataki T
Pharmacogenetics; 1998 Jun; 8(3):239-49. PubMed ID: 9682269
[TBL] [Abstract][Full Text] [Related]
19. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.
Pitarque M; von Richter O; Rodríguez-Antona C; Wang J; Oscarson M; Ingelman-Sundberg M
Hum Mutat; 2004 Mar; 23(3):258-66. PubMed ID: 14974084
[TBL] [Abstract][Full Text] [Related]
20. A novel single nucleotide polymorphism altering stability and activity of CYP2a6.
Ariyoshi N; Sawamura Y; Kamataki T
Biochem Biophys Res Commun; 2001 Mar; 281(3):810-4. PubMed ID: 11237731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
